SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo gets USFDA nod for generic anti-herpes tablets

01 Feb 2011 Evaluate

Aurobindo Pharma has received tentative approval from the US health regulator to manufacture and market generic Famciclovir tablets for the treatment of herpes virus infections.

The approval was granted by the United States Food and Drug Administration (USFDA) for Famciclovir tablets in the strengths of 125 mg, 250 mg and 500 mg,
Famciclovir tablets are the generic versions of Novartis Pharmaceuticals’ Famvir tablets, which are sold in the strengths of 125 mg, 250 mg and 500 mg. The product has a market size of approximately $170 million for the 12 months ending September 30, 2010, according to the IMS.

Aurobindo Pharma Share Price

1391.15 23.45 (1.71%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×